Lead optimisation

This new guide is brought to you by Eurofins Discovery. Download the guide to hit-finding tools that will accelerate your hit to lead and lead optimisation programmes for CNS, metabolic, oncology and other therapeutic areas. Synthetic, medicinal, and computational chemistry capabilities along with in house available diversity and focused libraries Small molecule and biologics targeted […]

Download the guide for hit-finding tools that will accelerate your hit to lead and lead optimisation programs for CNS, metabolic, oncology and other therapeutic areas. Synthetic, medicinal, and computational chemistry capabilities along with in house available diversity and focused libraries Small molecule and biologics targeted screening for GPCRs, kinases, ion channels, interleukins, checkpoints, novel targets […]

This paid-for advertorial by Eurofins Discovery appeared in Volume 23 – Issue 3, Summer 2022. In the following article, Luke Oostdyk, Lakshmi Anantharaman and Nicole Servant from Eurofins Discovery discuss how G-Protein Coupled Receptor screening and profiling can advance drug discovery programs.  The sheer number of understudied and orphan receptors in the G-Protein Coupled Receptor (GPCR)1 […]

Dunad Therapeutics has entered a strategic collaboration and license agreement with Novartis to generate orally bioavailable covalent and protein degrading small molecule drugs.  Dunad will be responsible for programme execution up to lead optimisation, while Novartis will contribute target and ligand knowledge as well as access to assays and models.  The platform uses mono-valent small molecules […]

1910 Genetics has been awarded an approximate $550,000 Phase I STTR grant by the National Institutes of Health (NIH).   The grant, received from the National Institute of Neurological Disorders and Stroke (NINDS) as part of the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, supports the discovery of a novel small molecule drug […]

Oncodesign, Covalab, CheMatech and ABX-CRO have partnered to launch the DRIVE-MRT (Molecular RadioTherapy) solution. Designed to offer therapeutic development in nuclear medicine, this encompasses theranostics, from therapeutic target validation, radiolabeled biological vector generation, lead optimisation, preclinical candidate drug generation and IND, to the design and management of clinical trials.  DRIVE-MRT is based on the companies’ joint expertise in nuclear medicine. It […]

X-Chem, provider of DNA-Encoded Library (DEL)-based discovery services, has acquired IntelliSyn, a Montreal-based drug discovery services company and its US-based sister company, AviSyn. The transaction will enable the company to offer a complete, seamless solution for screening, hit validation and lead optimisation on existing and new markets. Financial details of the deal have not been […]

The COVID-19 antiviral race: we’re all in this together By Uduak Grace Thomas In response to the COVID-19 pandemic, international scientists from academia and industry have pooled their expertise and resources to identify candidate compounds that inhibit the activity of the SARS-CoV-2 main protease, in order to develop a clinically effective antiviral. The aptly named […]

By Richard Gray The recent outbreak of COVID-19 has highlighted the need for fast and efficient development and production of vaccines for a whole gamut of pathogens, old and new. Microfluidics technologies can be used to accelerate the vaccine development process in a number of ways, not least in the directed evolution of the strains […]

State-of-the art facility is home to the company’s next-generation, fully automated platform for drug discovery. Arctoris Ltd, the developer of the world’s first fully automated drug discovery platform, today opened the doors to its new global headquarters and state-of-the-art research and development (R&D) facility in Oxford, UK. Housing the company’s proprietary technology and providing space […]